Axsome Therapeutics Financial Statements
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Axsome Therapeutics revenue and earnings
In fiscal 2025, Axsome Therapeutics generated $638.5 million in revenue, up 65.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Axsome Therapeutics reported a net loss of $183.2 million, compared with a loss of $287.2 million a year earlier. Gross margin was 92.6% (up from 91.4%) and operating margin -26.1%.
Diluted earnings per share came in at -$3.68.
Summary generated from market data by MetaCap's automated system. Methodology
Axsome Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 638.50M | 385.69M | 270.60M | 0 | — | — | — | — | — | — |
| Revenue growth (YoY) | +65.55% | +42.53% | — | — | — | — | — | — | — | — |
| Cost of Revenue | 47.48M | 33.30M | 26.07M | 5.20M | — | — | — | — | — | — |
| Gross Profit | 591.02M | 352.39M | 244.53M | -5.20M | — | — | — | — | — | — |
| Operating Expenses | 757.78M | 632.95M | 476.36M | 174.60M | 124.71M | 99.14M | 67.25M | 32.85M | 27.16M | 27.54M |
| Research & Development | 183.28M | 187.08M | 97.94M | 57.95M | 58.06M | 70.24M | 53.65M | 23.50M | 19.96M | 21.20M |
| Selling, General & Admin | 570.60M | 411.36M | 323.12M | 159.25M | 66.65M | 28.90M | — | — | — | — |
| Operating Income | -166.76M | -280.56M | -231.82M | -179.80M | -124.71M | -99.14M | -67.25M | -32.85M | -27.16M | -27.54M |
| Interest Expense | -15.93M | -21.58M | -20.03M | -9.66M | — | — | — | — | — | — |
| Pretax Income | -183.70M | -287.13M | -238.28M | -187.13M | -130.40M | — | — | — | — | — |
| Income Tax | -530.00K | 85.00K | 960.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -183.17M | -287.22M | -239.24M | -187.13M | -130.40M | -102.90M | -68.35M | -30.97M | -28.94M | -27.20M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 | -1.15 | -1.27 | -1.42 |
| EPS (Diluted) | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 | -1.15 | -1.27 | -1.42 |
| Shares Outstanding (Basic) | 49.75M | 47.91M | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M | 26.88M | 22.76M | 19.15M |
| Shares Outstanding (Diluted) | 49.75M | 47.91M | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M | 26.88M | 22.76M | 19.15M |
| EBITDA | -166.26M | -280.03M | -231.37M | -179.54M | -124.63M | -99.12M | -67.21M | -32.80M | -27.12M | -27.52M |
| Gross Margin | 92.56% | 91.37% | 90.37% | — | — | — | — | — | — | — |
| Operating Margin | -26.12% | -72.74% | -85.67% | — | — | — | — | — | — | — |
| Net Margin | -28.69% | -74.47% | -88.41% | — | — | — | — | — | — | — |
This table shows 10 annual periods of Axsome Therapeutics's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AXSM's reporting calendar. What is a income statement?